Too early to say anything on Kappa variant: UP doctor on Covid's new strain

An Uttar Pradesh doctor on Friday said it is too soon to comment on the Kappa variant as it's still a 'variant of interest'

Topics
Coronavirus Vaccine | Coronavirus | Coronavirus Tests

ANI 

Photo: Bloomberg
Photo: Bloomberg

As the emerging new strains of the Covid-19 virus are causing a lot of concern for the people, an Uttar Pradesh doctor on Friday said it is too soon to comment on the Kappa variant as it's still a 'variant of interest'.

"It is too early to say anything (on Kappa variant). When we tracked the patient's medical history, we found that he experienced a very high fever and breathing difficulty in a very short span of time. He was admitted in a very critical condition and died after almost 5 days," Dr Amresh Singh, assistant professor, and Head Microbiologist at BRD Medical College in Gorakhpur told ANI.

"We had sent around 72 samples to IGIB Gene Sequencing Centre in Delhi and received the reports for 30. The Delta variant was found in 27 of them, while Delta Plus was confirmed in 2, and 1 patient had Kappa variant," he added.

As per an official statement by the state government on Friday, two cases of the Kappa variant of Covid-19 have been detected in Uttar Pradesh after genome sequencing of 109 samples was done at the King George's medical college in Lucknow over the past few days.

"The Delta Plus variant of Covid-19 was found in 107 samples, while the Kappa variant was found in two samples. Both the variants are not new for the state. The facility of genome sequencing is being increased in the state," the statement issued post-Chief Minister Yogi Adityanath's routine review meeting stated.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read our full coverage on Coronavirus Vaccine
First Published: Sun, July 11 2021. 09:03 IST
RECOMMENDED FOR YOU